MITAKY™ High-Tech Corporation Japan｜株式会社ミタキハイテク日本

MITAKY Collaborates with Vietnam’s Ministry of Science and Technology on Agricultural Digitalisation in Thua Thien Hue

Yamada Haruko｜山田春子 — Thu, 26 Sep 2024 12:05:21 +0000

ABOUT US ≫ Newsroom ≫ Official News Release

MITAKY Collaborates with Vietnam's Ministry of Science and Technology on Agricultural Digitalisation in Thua Thien Hue

Japanese Technology Transfer Service: Agricultural Digitalisation

Hue, Vietnam — On July 26, 2023, facilitated by the Office of Science & Technology at Consulate General of Vietnam in Osaka, MITAKY’s Representative Director & CEO, Mr. Minamoto, led a key meeting with the Thua Thien Hue’s Department of Science and Technology (under Vietnam’s Ministry of Science & Technology). The meeting focused on introducing Japan’s advanced WAGRI digital agricultural platform and exploring its potential integration into Vietnamese agriculture. Discussions also highlighted the applications of Japanese smart farming technologies such as precision farming and agricultural robots to enhance local agricultural practices through digital transformation.

Key participants included Mr. Nguyen Kim Tung, Deputy Director of the Department of Science and Technology; Mr. Le Dinh Hoai Vu, Director of the Center for Science and Technology Advancement; the Head of Osaka Science and Technology Office; and representatives from the Department of Agriculture and Rural Development, Information and Communications, and local agricultural cooperatives of Thua Thien Hue Province.

During the meeting, Mr. Minamoto outlined how Japan’s automation technologies could transform Vietnamese agriculture, from harvesting efficiency to sustainable crop management. Discussions also covered challenges faced by local farmers and the potential for implementing Japanese innovations to address these issues. A field survey in Quảng Thọ followed to assess specific needs on the ground.

MITAKY remains committed to fostering innovation and sustainability in global agriculture through partnerships like this.

About MITAKY

MITAKY High-Tech Corporation is one of leading providers of cutting-edge technology solutions across various industries, with a strong focus on innovation and sustainability. Headquartered in ancient city of Kyoto Japan, MITAKY specialises in leveraging digital technologies to enhance efficiency and promote environmental stewardship, particularly in the precision agriculture sector. The company is committed to creating solutions that address global challenges and improve the quality of life through technological advancement.

For more information, please contact: business@mitaky.co.jp

About Thua Thien Hue's Department of Science and Technology (MOST)

The Thua Thien Hue Department of Science and Technology operates under Vietnam’s Ministry of Science and Technology. It is responsible for promoting scientific research, technological development, and innovation within the province. The department supports the application of advanced technologies across various sectors, including agriculture, to drive economic growth and sustainability. It plays a vital role in fostering collaboration between local industries and international partners to enhance the region’s technological capabilities.

Further Reads

︎ For further featured news release by Ministry of Science & Technology (in Vietnamese): Làm việc với chuyên gia Nhật Bản liên quan đến hợp tác triển khai công nghệ số hóa nông nghiệp

︎ Asia Development Bank – Agriculture, Natural Resources and Rural Development Sector Assessment, Strategy and Road Map – Viet Nam 2021–2025

OUR Related Products & Services

MITAKY High-Tech Corporation｜Recruitment｜Regenerative Medical Liaison (Associate)

Yamada Haruko｜山田春子 — Wed, 24 Apr 2024 06:14:18 +0000

ABOUT US ≫ Recruitment ≫ MTK-South-Southeast-Asia-R061231

Regenerative Medical Liaison (Associates)

Regenerative Medical Liaison (Associate) – South and Southeast Asian Nations

Starting Date:

Upon agreement.

Company Overview:

MITAKY High-Tech®｜㈱源尊京ハイテク is a technology corporation based in Kyoto, Japan. Our core mission is to heal the world by our Excellence of Japanese regenerative medicines. We specialise in R&D on Regenerative Techs, Bio-sensors, Agri Robots, and provide Japanese high-technologies transferring and ministerial levelled strategies advising services. With a focus on cutting-edge research and development, we strive to improve patients’ lives worldwide. Other than conducting R&D on latest regenerative medicines technology, MITAKY also provides solutions on high-quality medical tourism support services through our expertise in the field of medical and high-quality treatment programs information worldwide.

Position Summary:

We are seeking dynamic and self-motivated individuals to join our team as Regenerative Medical Liaisons (Associates) in each key cities across South and Southeast Asia. As a Regenerative Medical Liaison, you will play a vital role in introducing and referring new customers to our high-quality medical and healthcare tourism support services, facilitating their journey to Japan for high-quality regenerative medical treatments.

Working Location (1):

Region: South Asia
Country/Territory: India
Total number of position: four (4) people

Location (City)	Mumbai	New Delhi
Position Category	Associate・Partner	Associate・Partner
Number of position	two (2) people	two (2) people

Working Location (2):

Region: Southeast Asia
Country/Territory: Singapore
Total number of position: one (1) people

Location (City)	Singapore
Position Category	Associate・Partner
Number of position	one (1) person

Working Location (3):

Region: Southeast Asia
Country/Territory: The Philippines
Total number of position: four (4) people

Location (City)	Manila	Quezon City
Position Category	Associate・Partner	Associate・Partner
Number of position	two (2) people	two (2) people

Working Location (4):

Region: Southeast Asia
Country/Territory: Vietnam
Total number of position: five (5) people

Location (City)	Danang	Hochiminh
Position Category	Associate・Partner	Associate・Partner
Number of position	three (3) people	two (2) people

Key Responsibilities:

Networking: Establish and maintain strong relationships with medical professionals, hospitals, clinics, and healthcare organisations to promote our services.
Customer Acquisition: Proactively engage with potential clients to understand their medical needs and introduce our regenerative medical treatments and services.
Consultative Selling: Provide detailed information about our treatments, benefits, and the process of receiving medical care in Japan. Address client inquiries and concerns effectively.

Qualifications:

Bachelor graduation (or MA, MD, PhD) in Business Administration, Marketing, Healthcare Management, or related field.
Medical Industry basic knowledge;
Understanding the Needs of Customers;
Networking Ability: possess an extensive network of high-profiled contacts within various industries, including business, politics, entertainment, and other high-profile sectors;
Strong Communication Skill: Excellent verbal and written communication skills are essential for effectively liaising and counselling;
Proven experiences in high value products/services sales, relationship management and high-profiled networking are favourable;
Current resident of a country you apply the position for;
Familiarity with the healthcare systems and regulations in South and Southeast Asian countries;
Fluency and proficiency in local languages (e.g., Hindi, Tamil, Tagalog, Malay, Vietnamese) as per assigned city requirements.

Our offers:

Performance-based commission incentives;
Renowned Japanese regenerative medicines industry’s information access opportunity;
You are an Associate (NOT our employee), so that your current positions/jobs can be still continued.

How to Apply:

Please send your Application includes below documents in electronic format (Word or PDF) to Human Resource Division, MITAKY High-Tech Corporation Japan K.K, by Email address: 『HR★mitaky.co.jp』(Please replace ★ with @ mark):

Your Résumé in English (with your photo attached, free form);
Copies of Relevant Certificates / Qualification;
Your Motivational Letter to this position.

※Please write into the subject line “[Your Name] MITAKY RegMed Associateship Application” to ensure timely processing of your application. Only shortlisted candidates will be contacted for interviews.

Application Deadline:

Until filled.

MITAKY High-Tech Corporation is an equal opportunity employer and values diversity in the workplace. We offer and encourage all qualified individuals to apply. For more details of this current position in Regenerative Medicines Sector of MITAKY Group, the potential Candidates can download the Recruitment Policy: Associate Requirement & Job Description below:

(PDF, 13 Pages, 3,654 kB, English & Japanese)

Additional Information:

Please note that the deadline for applications is 17:50 on the day mentioned in the above field “Application Deadline”. We advise you to allow enough time to complete and submit your full application, since only applications completed and submitted before the deadline will be considered;
Please be aware that the deadline for submitting applications is considered to be the time zone for the country mentioned in the above field “Application Deadline”;
MITAKY High-Tech Corporation does not pay for travel related expense incurred in interviews (including Security Check) or accept any financial risk, including cancelation or reschedule costs. MITAKY High-Tech Corporation will not meet the costs connected with relocation if offered a position.

MITAKY High-Tech Corporation｜Recruitment｜Senior Medical Advisor

Yamada Haruko｜山田春子 — Sat, 20 Apr 2024 09:50:40 +0000

ABOUT US ≫ Recruitment ≫ MTK-Abu-Dhabi-R060622

Senior Medical Adviser in MITAKY (Abu Dhabi)

Job Title: Senior Medical Adviser (Biotechnology) – Abu Dhabi, United Arab Emirates

Starting Date:

Upon agreement.

Company Overview:

MITAKY High-Tech®｜㈱源尊京ハイテク is a technology corporation based in Kyoto, Japan. Our core mission is to connect Japan and the rest of the world through high-technologies and visionary strategies. We specialise in R&D on Regenerative Techs, Bio-sensors, Agri Robots, and provide Japanese high-technologies transferring and ministerial levelled strategies advising services. With a focus on cutting-edge research and development, we strive to improve patients’ lives worldwide. We are currently seeking one (1) experienced and highly motivated Senior Medical Adviser to join our dynamic team in Abu Dhabi.

Position Summary:

As a Senior Medical Adviser, you will play a critical role in providing medical and scientific expertise to support the development and commercialisation of our products. You will be responsible for engaging with healthcare professionals, key opinion leaders, and internal stakeholders to ensure the successful execution of our medical strategies. This position offers an exciting opportunity to contribute to the advancement of groundbreaking therapies in a fast-paced and collaborative environment.

Working Location:

Region: West Asia, Middle East
Country/Territory: Al-Imārāt al-ʿArabiyyah al-Muttaḥidah (United Arab Emirates)
Location (City): Abu Dhabi
Type of position: Hybrid・Full-time

Key Responsibilities:

Medical Strategy Development: Develop and implement medical strategies aligned with business objectives to support the successful launch and commercialisation of products.
Medical Affairs Support: Provide medical and scientific expertise to internal teams, including clinical development, regulatory affairs, and marketing, to ensure alignment and compliance with medical standards and regulations.
KOL Engagement: Establish and maintain relationships with key opinion leaders and healthcare professionals to drive scientific exchange and gather insights to inform medical strategies.
Scientific Communication: Develop and deliver scientific presentations, publications, and educational materials to support product awareness and knowledge dissemination.
Clinical Trial Support: Provide medical oversight and support for clinical trials, including protocol development, safety monitoring, and data interpretation.
Medical Education: Develop and deliver medical education programs and materials for internal teams and external stakeholders to enhance understanding of disease areas and product profiles.
Medical Information: Serve as a medical resource for internal and external inquiries, ensuring accurate and timely responses to medical and scientific questions.
Regulatory Support: Collaborate with regulatory affairs teams to provide medical input for regulatory submissions and ensure compliance with relevant regulations and guidelines.

Qualifications:

Medical Doctor (MD) or equivalent degree; specialisation in a relevant therapeutic area preferred.
Minimum of 5 years of experience in medical affairs or clinical development within the biotechnology or pharmaceutical industry.
Strong understanding of medical and scientific principles, with expertise in a relevant therapeutic area.
Excellent communication and presentation skills, with the ability to effectively engage with internal and external stakeholders.
Experience with government relations is a plus.
Proven ability to develop and implement medical strategies to support product development and commercialisation.
Experience working in a cross-functional team environment and collaborating with colleagues across multiple disciplines.
Knowledge of regulatory requirements and guidelines related to medical affairs and clinical development.
Current resident in UEA (regardless of nationality and gender)
Fluent in English proficiency (TOIEC score 800 or above); proficiency in Japanese language (JLPT N4 or above) is a plus.
IT skills: Microsoft Excel, Word, PowerPoint, Teams, Outlook

Our offers:

A fascinating role in the heart of Middle East – Abu Dhabi City in an exciting global environment.
Competitive salary range and benefits package
Paid vacation
UAE and some Japanese public holidays

How to Apply:

Your Résumé in English (with your photo attached);
A Letter of Interest;
Salary Expectation;

※Please write into the subject line “MITAKY – Senior Medical Adviser” to ensure timely processing of your application. Only shortlisted candidates will be contacted for interviews (Online & In-person).

Application Deadline:

June 22, 2024 11:55 PM GMT+9.

MITAKY High-Tech Corporation is an equal opportunity employer and values diversity in the workplace. We encourage all qualified individuals to apply.

Additional Information:

Please note that the deadline for applications is 23:55 on the day mentioned in the above field “Application Deadline”. We advise you to allow enough time to complete and submit your full application, since only applications completed and submitted before the deadline will be considered;
Please be aware that the deadline for submitting applications is considered to be the time zone for the country mentioned in the above field “Application Deadline”;
Candidates may be requested to provide performance assessments and authorisation to conduct verification checks of past and present work, character, education, military and police records to ascertain any and all information which may be pertinent to the employment qualifications;
MITAKY High-Tech Corporation does not pay for travel related expense incurred in interviews (including Security Check) or accept any financial risk, including cancelation or reschedule costs. MITAKY High-Tech Corporation will not meet the costs connected with relocation if offered a position.

MITAKY Technology Review｜Regenerative Medicine in Japan

Yamada Haruko｜山田春子 — Mon, 08 Apr 2024 02:32:35 +0000

MITAKY Technology Review ≫ Regenerative Medicine ≫ Regenerative Medicine in Japan

Regenerative Medicine in Japan

By N. Wada, MITAKY Technology Review

Japan’s Commitment to Regenerative Medicine

Regenerative Medicine Products Market Size in Japan and Worldwide until 2050

In Japan, the regenerative medicine market is poised for significant expansion, propelled by supportive government policies, technological innovations, and a strong ecosystem of research institutions and biotechnology companies. The market size in Japan was estimated to be around $2.5 billion in 2022, with projections indicating a CAGR of approximately 30% from 2022 to 2027, reaching a value of over $10 billion by 2027.

As of the world, the global regenerative medicine market was valued at around $24 billion and is expected to grow at a compound annual growth rate (CAGR) of approximately 23% from 2022 to 2027, reaching a value of over $90 billion by 2027. This growth trajectory is fueled by the commercialisation of innovative products across various therapeutic areas, including orthopedics, cardiovascular diseases, and oncology.

Looking further ahead to 2050, the regenerative medicine market is expected to continue its upward trajectory, driven by advancements in stem cell biology, tissue engineering, and gene editing technologies. While precise forecasts beyond 2027 are speculative, analysts anticipate sustained growth fueled by the increasing demand for regenerative therapies to address aging populations, chronic diseases, and unmet medical needs.

By 2050, the global regenerative medicine market could potentially exceed $500 billion, with Japan continuing to play a significant role as a key innovator and market leader in this transformative field. Continued investment in research, regulatory harmonisation, and healthcare infrastructure will be essential to realise the full potential of regenerative medicine and improve patient outcomes worldwide.

Regenerative Medicine: A Paradigm Shift

Regenerative medicine represents a paradigm shift in healthcare, aiming to restore the structure and function of damaged tissues and organs through the stimulation of the body’s own repair mechanisms or by introducing exogenous cells, tissues, or biomaterials. Stem cell therapy, tissue engineering, and gene therapy are key pillars of regenerative medicine, offering promising avenues for treating a wide range of conditions, from cardiovascular diseases to neurodegenerative disorders.

Japan's Commitment to Regenerative Medicine

Japan has emerged as a global hub for regenerative medicine, driven by a combination of scientific expertise, government support, and regulatory reforms. In 2014, the Japanese government implemented the Regenerative Medicine Promotion Act, streamlining the approval process for regenerative medicine products and establishing a framework for their clinical development and commercialization. This legislation marked a significant milestone, facilitating collaboration between academia, industry, and regulatory agencies to accelerate the translation of scientific discoveries into clinical applications.

Breakthrough Products and Innovations in Japan

Several breakthroughs in regenerative medicine have originated from Japan, demonstrating the country’s leadership in this field. One notable example is induced pluripotent stem cells (iPSCs), pioneered by Dr. Shinya Yamanaka of Kyoto University. iPSCs are reprogrammed adult cells capable of differentiating into various cell types, offering a potentially limitless source of patient-specific cells for transplantation and drug discovery. The discovery of iPSCs earned Dr. Yamanaka the Nobel Prize in Physiology or Medicine in 2012 and sparked a surge of research in regenerative medicine worldwide.

Building upon this foundation, Japanese companies and research institutions have developed a diverse array of regenerative medicine products targeting different therapeutic areas. For instance, Healios, a biotechnology company based in Tokyo, is conducting clinical trials of regenerative cell therapy for ischemic stroke, a leading cause of disability worldwide. By transplanting neural stem cells derived from human iPSCs into the brains of stroke patients, Healios aims to promote tissue repair and functional recovery, potentially revolutionising the treatment of this devastating condition.

In the field of tissue engineering, Organ Technologies is pioneering hair regeneration therapies for the treatment of baldness. Leveraging advances in cell culture techniques and 3D bio-printing, the company aims to engineer hair follicles from patients’ own cells and implant them into the scalp to stimulate hair growth. This innovative approach offers a promising solution for millions of individuals suffering from alopecia, addressing a significant unmet medical need.

Furthermore, Japan has made significant strides in the development of gene therapies, particularly for genetic disorders and rare diseases. An illustrative example is the work of Dr. Fumihiro Sugiyama and his team at Osaka University, who are investigating gene editing technologies such as CRISPR-Cas9 to correct genetic mutations underlying inherited retinal diseases. By precisely targeting and repairing faulty genes in retinal cells, these therapies hold the potential to restore vision and improve the quality of life for patients with debilitating eye conditions.

Regulatory Framework

While Japan has made commendable progress in advancing regenerative medicine, the field faces several regulatory and logistical challenges. Despite the streamlined approval process introduced by the Regenerative Medicine Promotion Act, ensuring the safety and efficacy of novel therapies remains paramount. Regulatory agencies such as the Pharmaceuticals and Medical Devices Agency (PMDA) play a critical role in evaluating and monitoring regenerative medicine products, balancing the need for innovation with rigorous oversight to protect patient safety.

Challenges

Moreover, the scalability and cost-effectiveness of regenerative medicine products pose practical challenges for widespread adoption. Manufacturing complex cell-based therapies at a commercial scale requires sophisticated infrastructure and quality control measures, which can drive up production costs and limit accessibility for patients. Addressing these challenges will require continued investment in research and development, as well as collaboration between academia, industry, and regulatory bodies to optimize manufacturing processes and streamline supply chains.

Future and Opportunities

Looking ahead, the future of regenerative medicine in Japan appears promising, with ongoing research efforts poised to yield further breakthroughs and therapeutic innovations. Advances in stem cell biology, tissue engineering, and gene editing technologies continue to expand the possibilities for regenerative therapies, offering hope for patients with degenerative diseases and chronic conditions.

Furthermore, collaborations between academia, industry, and government are essential for translating scientific discoveries into tangible medical solutions and driving the growth of Japan’s regenerative medicine sector. Initiatives such as the Japan Agency for Medical Research and Development (AMED) provide critical funding and infrastructure support for regenerative medicine research, fostering a vibrant ecosystem of innovation and entrepreneurship.

References

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.
Cyranoski, D. (2014). Japanese woman is first recipient of next-generation stem cells. Nature, 513(7519), 287.
Matsui, H., & Watanabe, E. (2020). Regenerative medicine in Japan today: A summary of the legislation and achievements. Cell Stem Cell, 27(3), 404-408.
Sugiyama, F., & Ikeda, Y. (2019). CRISPR-Cas9-based genome editing for the development of next-generation CAR-T cell therapy against solid tumors. Cancer Science, 110(10), 2683-2689.
Organ Technologies Inc. (2024). Hair Regeneration.
Healios K.K. (2024). Clinical Trials.
Yamasaki, D., Arai S. (2014). Nikkei Asia – Japan’s stem-cell therapy progress accelerates

Related reviews

Stem Cells

Adipose-Derived Stem Cells (ADSCs)

iPS Cells (Induced Pluripotent Stem Cells)

MITAKY Technology Review｜Regenerative Medicine｜iPS Cells

Yamada Haruko｜山田春子 — Mon, 08 Apr 2024 00:36:36 +0000

MITAKY Technology Review ≫ Regenerative Medicine ≫ Induced Pluripotent Stem Cells

iPS Cells (Induced Pluripotent Stem Cells)

By N. Wada, MITAKY Technology Review

Unlocking Hope: How Induced Pluripotent Stem Cells (iPS Cells) are Revolutionising Regenerative Medicine.

Summary

Induced Pluripotent Stem Cells (iPS cells or iPSCs), was first introduced in 2006 by a Japanese stem cell researcher and a Nobel Prize laureate – Prof. YAMANAKA Shinya of Kyoto University, Japan. iPS cells hold immense potential due to their ability to differentiate into various cell types, mirroring embryonic stem cells’ characteristics. They also represent a groundbreaking technology with transformative implications for regenerative medicine. Their versatility, combined with their ability to bypass ethical controversies associated with embryonic stem cells, positions iPS cells at the forefront of biomedical research and therapeutic innovation. As researchers continue to unravel the intricacies of iPS cell biology and overcome existing challenges, the field holds the promise of delivering personalised, effective treatments for a wide range of debilitating diseases, ushering in a new era of regenerative medicine.

Understanding iPS Cells

Induced Pluripotent Stem Cells (iPS cells) are reprogrammed adult cells, typically derived from fibroblasts or other somatic cells, through the introduction of specific transcription factors such as Oct3/4, Sox2, Klf4, and c-Myc. This reprogramming process resets the cellular epigenetic landscape, reverting the cells to a pluripotent state akin to embryonic stem cells (ESCs), without the ethical concerns associated with the use of embryos. iPS cells possess remarkable self-renewal capacity and the potential to differentiate into virtually any cell type in the human body, making them invaluable in regenerative medicine.

Five Key Characteristics of iPS Cells

Pluripotency (Versatility): iPS cells possess the unique ability to differentiate into virtually any cell type in the human body, mirroring embryonic stem cells’ versatility.
Reprogrammability: Through the introduction of specific transcription factors, iPS cells can be reprogrammed from adult somatic cells, offering a non-controversial alternative to embryonic stem cells.
Disease Modeling: iPS cells enable the creation of disease-specific cell models, providing invaluable insights into disease mechanisms, drug discovery, and personalised medicine.
Patient Specificity: By deriving iPS cells from patient samples, researchers can develop personalised therapies and drug screening platforms tailored to individual genetic profiles.
Potential for Regenerative Medicine: iPS cells hold promise for cell replacement therapies, tissue regeneration, and transplantation, offering hope for treating a wide range of degenerative diseases and injuries.

Applications of iPS Cells in Regenerative Medicine:

1. Disease Modeling:
iPS cells offer a powerful platform for modeling human diseases in vitro, allowing researchers to recapitulate disease phenotypes and study underlying mechanisms. By reprogramming patient-derived cells into iPS cells and subsequently differentiating them into disease-relevant cell types, scientists can investigate disease progression, screen potential therapeutics, and personalize treatment approaches. For instance, researchers have utilized iPS cells to model neurodegenerative disorders like Parkinson’s and Alzheimer’s disease, cardiovascular diseases, and genetic disorders such as Duchenne muscular dystrophy.

2. Drug Discovery and Development:
The ability to generate patient-specific cell types from iPS cells facilitates personalised drug screening and development. iPS cell-derived models enable researchers to evaluate drug efficacy, toxicity, and side effects in a more physiologically relevant context, potentially reducing the attrition rates of drug candidates during clinical trials. Moreover, iPS cell-based platforms allow for the identification of novel therapeutic targets and the development of precision medicines tailored to individual patients, thereby advancing personalized healthcare.

3. Cell Replacement Therapy:
One of the most promising applications of iPS cells lies in cell replacement therapies for treating degenerative diseases and tissue injuries. Through directed differentiation protocols, iPS cells can be guided to differentiate into specific cell types required for tissue regeneration, such as cardiomyocytes for heart repair, dopaminergic neurons for Parkinson’s disease, and pancreatic β cells for diabetes. These differentiated cells can then be transplanted into patients to restore tissue function, offering potential cures for previously incurable conditions.

Challenges

While iPS cells hold immense promise, several challenges need to be addressed to fully realise their potential in regenerative medicine. These include concerns regarding the safety and efficacy of iPS cell-based therapies, issues related to the scalability and standardisation of cell manufacturing processes, and ethical considerations surrounding the use of genetic manipulation techniques. Additionally, advancements in gene editing technologies such as CRISPR-Cas9 hold promise for enhancing the precision and efficiency of iPS cell reprogramming and differentiation.

A journey to stem cell research of Prof. Yamanaka

Professor Yamanaka Shinya’s began his journey with a passion for medicine and a desire to alleviate human suffering. After earning his medical degree from Kobe University in Japan in 1987, Yamanaka embarked on a career in orthopedic surgery. However, he soon realised that surgery alone could not address the root causes of many diseases.

Driven by a desire to delve deeper into the mechanisms of disease and develop more effective treatments, Yamanaka decided to pursue a career in basic research. He joined the Gladstone Institute of Cardiovascular Disease at the University of California, San Francisco, where he began studying the genetic factors underlying heart disease.

Inspired by the potential of embryonic stem cells to revolutionise regenerative medicine, Dr. Yamanaka shifted his focus to stem cell research. He became intrigued by the idea of reprogramming adult cells into a pluripotent state, thereby bypassing the ethical concerns associated with embryonic stem cells.

In 2004, Dr. Yamanaka returned to Japan and joined Kyoto University as a professor at the Center for iPS Cell Research and Application (CiRA). At Kyoto University, he had the resources and support to pursue his groundbreaking research on induced pluripotent stem cells (iPS cells).

Through tireless experimentation and innovative thinking, Prof. Yamanaka and his team succeeded in reprogramming adult cells into iPS cells in 2006. This achievement not only established Yamanaka Shinya as a leading figure in stem cell research but also positioned Kyoto University as a global hub for regenerative medicine.

Prof. Yamanaka’s groundbreaking work at Kyoto University earned him numerous accolades, including the Nobel Prize in Physiology or Medicine in 2012. Today, he continues to lead pioneering research at CiRA, seeking to harness the potential of iPS cells to develop innovative therapies for a wide range of diseases and injuries.

References

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.
Yu, J., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917-1920.
Trounson, A., & DeWitt, N. D. (2016). Pluripotent stem cells progressing to the clinic. Nature Reviews Molecular Cell Biology, 17(3), 194-200.
Saha, K., & Jaenisch, R. (2009). Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell, 5(6), 584-595.
Mandai, M., et al. (2017). Autologous induced stem-cell-derived retinal cells for macular degeneration. New England Journal of Medicine, 376(11), 1038-1046.
Cyranoski, D. (2018). Japan approves first human-animal embryo experiments. Nature, 564(7734), 16-17.

Related reviews

Regenerative Medicine in Japan

Stem Cells

Adipose-Derived Stem Cells (ADSCs)

MITAKY Technology Review｜Regenerative Medicine｜Adipose-Derived Stem Cells

Yamada Haruko｜山田春子 — Sun, 07 Apr 2024 13:53:55 +0000

MITAKY Technology Review ≫ Regenerative Medicine ≫ Adipose-Dereived Stem Cells

Adipose-Derived Stem Cells (ADSCs)

By S. Hamada, MITAKY Technology Review

Harnessing the Power of Adipose-Derived Stem Cells (ADSCs) in Regenerative Medicine

Summary

Adipose-Derived Stem Cells (ADSCs) represent a powerful tool in the field of regenerative medicine, offering immense potential for tissue repair, regeneration, and disease treatment. Their unique properties, including multipotent differentiation capabilities and immunomodulatory effects, make them highly attractive for a wide range of therapeutic applications.

From orthopedic injuries to dermatological conditions, cardiovascular diseases, and neurodegenerative disorders, ADSC-based therapies hold promise for transforming the way we approach healthcare and disease treatment. As research continues to advance and technology evolves, ADSCs are poised to play a central role in shaping the future of regenerative medicine, offering hope to millions of patients worldwide.

Understanding Adipose-Derived Stem Cells (ADSCs)

ADSCs are a type of mesenchymal stem cell (MSC) that can be easily isolated from adipose tissue through minimally invasive procedures such as liposuction or lipoaspiration. Unlike embryonic stem cells, ADSCs are derived from adult tissue, bypassing ethical concerns and regulatory hurdles associated with embryonic stem cell research. The abundance of adipose tissue in the body makes ADSCs readily accessible, offering a plentiful and reliable source for therapeutic use.

Characteristics and Properties of ADSCs

Multipotent Differentiation: ADSCs have the capacity to differentiate into various cell lineages, including adipocytes, osteoblasts, chondrocytes, and myocytes. This versatility enables ADSCs to contribute to the regeneration of diverse tissues and organs.
Immunomodulatory Properties: ADSCs exhibit immunomodulatory effects by suppressing inflammatory responses and regulating immune cell activity. This feature is particularly beneficial for treating autoimmune disorders and inflammatory conditions.
High Proliferative Capacity: ADSCs possess a high proliferation rate, allowing for the generation of large quantities of cells for therapeutic purposes. This scalability is critical for clinical applications requiring substantial cell numbers.

Four Applications of ADSCs in Regenerative Medicine

1. Tissue Regeneration and Repair:
ADSCs hold promise for the regeneration of musculoskeletal tissues, including bone, cartilage, and muscle. Studies have demonstrated the effectiveness of ADSCs in promoting bone healing, accelerating fracture repair, and mitigating cartilage degeneration. ADSC-based therapies offer potential treatments for conditions such as osteoarthritis, osteoporosis, and musculoskeletal injuries, providing alternatives to conventional treatments like joint replacement surgery.

2. Dermatological Applications:
ADSCs play a crucial role in skin regeneration and wound healing. Their ability to stimulate tissue repair, angiogenesis, and collagen synthesis makes them valuable assets in treating chronic wounds, burns, and dermatological conditions. ADSC-based therapies offer potential solutions for improving wound closure rates, reducing scar formation, and enhancing the cosmetic outcomes of reconstructive procedures.

3. Orthopedic Medicine:
ADSCs hold promise for cardiac regeneration and repair following myocardial infarction (MI). Studies have shown that ADSC transplantation can improve cardiac function, reduce scar formation, and stimulate angiogenesis in animal models of MI. ADSC-based therapies offer potential treatments for heart failure, ischemic heart disease, and other cardiovascular conditions, providing hope for patients with limited treatment options.

4. Neurological Disorders and Injury Repair:
ADSCs offer potential treatments for neurological disorders and injuries, including stroke, spinal cord injury, and neurodegenerative diseases. Preclinical studies have shown that ADSC transplantation can promote neurogenesis, enhance neuronal survival, and improve functional recovery in animal models of neurological damage. ADSC-based therapies hold promise for restoring neurological function and improving quality of life for patients with debilitating conditions.

Challenges and Future Directions

Despite the significant progress in ADSC research, several challenges remain to be addressed. Standardization of isolation and culture protocols is essential to ensure the consistency and safety of ADSC-based therapies. Moreover, the long-term safety and efficacy of these therapies need to be rigorously evaluated through clinical trials to establish their viability as mainstream treatment options.

In addition, regulatory frameworks governing the use of ADSCs in regenerative medicine must be established to ensure ethical and responsible practices. The ethical considerations surrounding stem cell research, including issues of informed consent, patient safety, and equitable access to treatment, must be carefully addressed to foster public trust and confidence in this emerging field.

Looking ahead, the future of ADSCs in regenerative medicine appears promising, with ongoing research efforts focused on refining techniques, optimizing protocols, and exploring new therapeutic avenues. Advances in stem cell technology, tissue engineering, and gene editing hold the potential to further enhance the therapeutic capabilities of ADSCs and revolutionize the landscape of regenerative medicine.

Citations:

Huang, J. I., & Zuk, P. A. (2002). Adipose-derived stem cells: a new source for musculoskeletal regeneration. Journal of the American College of Surgeons, 195(3), 329-334.
Rigotti, G., Marchi, A., Galie, M., Baroni, G., Benati, D., Krampera, M., … & Sbarbati, A. (2007). Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plastic and reconstructive surgery, 119(5), 1409-1422.
Cai, L., Johnstone, B. H., Cook, T. G., Tan, J., Fishbein, M. C., Chen, P. S., & March, K. L. (2009). IFATS collection: Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem cells, 27(1), 230-237.
Cui, L., Jiang, J., Wei, L., Zhou, X., Fraser, J. L., Snider, B. J., … & Lu, M. (2007). Transplantation of embryonic stem cells improves nerve repair and functional recovery.

Related reviews

iPS Cells (Induced Pluripotent Stem Cells)

Regenerative Medicine in Japan

Stem Cells

MITAKY Technology Review｜Regenerative Medicine｜Stem Cells

Yamada Haruko｜山田春子 — Sat, 06 Apr 2024 11:45:22 +0000

MITAKY Technology Review ≫ Regenerative Medicine ≫ Stem Cells

Stem Cells

By H. Takashima, MITAKY Technology Review

What are stem cells? and what can stem cells do?

Summary

Stem cell therapy stands as a light of hope, offering transformative possibilities in regenerative medicine. Stem cell therapy represents a revolutionary paradigm shift in regenerative medicine, offering unprecedented opportunities for treating a myriad of diseases and injuries. With their unique regenerative properties, stem cells hold the potential to transform healthcare and improve patients’ lives. While significant progress has been made, continued research and collaboration are essential to overcome challenges and unlock the full therapeutic potential of stem cell therapy. By embracing interdisciplinary approaches and addressing ethical considerations, we can harness the power of stem cells to usher in a new era of regenerative medicine.

Three key characteristics of stem cells

1. Self-Renewal Capability:
Stem cells possess the unique ability to self-renew, allowing them to undergo numerous cell divisions while maintaining their undifferentiated state. This property ensures a continuous supply of stem cells for tissue maintenance and repair.

2. Differentiation Potential:
Stem cells possess the capacity to differentiate into specialised cell types of various lineages. This differentiation potential allows them to generate a wide range of cell types, including neurons, muscle cells, and blood cells, among others, depending on their lineage and developmental stage.

3. Plasticity:
Stem cells exhibit plasticity, the ability to differentiate into cell types beyond their lineage under certain conditions. This property enables stem cells to adapt to different microenvironments and tissues, broadening their therapeutic potential in regenerative medicine.

Types of Stem Cell Therapy

Stem cell therapy encompasses various approaches, each tailored to meet specific medical needs and conditions. Autologous stem cell therapy involves harvesting stem cells from the patient’s own body, typically from bone marrow or adipose tissue, and then reintroducing them into the affected area. This minimizes the risk of rejection or immune response, as the cells are derived from the patient themselves.

On the other hand, allogeneic stem cell therapy utilises stem cells sourced from a donor, such as umbilical cord blood or another compatible individual. While allogeneic stem cell therapy offers the advantage of readily available cells for immediate use, careful matching is essential to mitigate the risk of rejection or graft-versus-host disease.

Applications in Regenerative Medicine

Stem cell therapy holds immense promise in regenerative medicine due to its potential to repair, replace, or regenerate damaged tissues and organs. One of its primary applications is in the treatment of degenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and spinal cord injuries. By replenishing damaged or dysfunctional cells with healthy ones, stem cell therapy offers the prospect of slowing disease progression and improving patients’ quality of life.

Furthermore, stem cell therapy has shown considerable efficacy in tissue regeneration and wound healing. For instance, it can be employed to stimulate the regeneration of cardiac tissue following a heart attack, promote bone growth in fractures, and accelerate the healing of chronic wounds. These regenerative properties make stem cell therapy a promising avenue for addressing a myriad of medical conditions.

Recent Advances and Future Directions

In recent years, significant advancements have propelled stem cell research to new heights, paving the way for innovative therapies and treatments. One notable breakthrough is the development of induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed to exhibit embryonic stem cell-like properties. iPSCs offer the potential for personalized medicine, enabling the generation of patient-specific stem cells for therapeutic purposes.

Moreover, researchers are exploring the synergistic potential of stem cells with other cutting-edge technologies such as gene editing and tissue engineering. These interdisciplinary approaches hold promise for enhancing the therapeutic efficacy of stem cell therapy and addressing current limitations.

Challenges and Ethical Considerations

Despite its tremendous potential, stem cell therapy faces challenges and ethical dilemmas that must be addressed. One major concern is the risk of tumorigenicity, wherein transplanted stem cells may give rise to tumors or exhibit uncontrolled growth. Efforts are underway to develop strategies to mitigate this risk, including stringent pre-screening of cells and genetic modifications to enhance their safety profile.

Additionally, ethical considerations surround the use of embryonic stem cells, as their derivation involves the destruction of human embryos. While alternative sources such as iPSCs have alleviated some of these ethical concerns, ongoing debate persists regarding the moral implications of stem cell research and therapy.

Understanding Stem Cells

At the heart of stem cell therapy lies the intrinsic properties of stem cells themselves. Stem cells are undifferentiated cells characterized by their capacity for self-renewal and differentiation into specialized cell types. Broadly categorized into embryonic stem cells (ESCs) and adult stem cells, they play a pivotal role in the body’s natural healing processes.

Embryonic stem cells (ESCs) are derived from early-stage embryos and possess pluripotent capabilities, meaning they can give rise to any cell type in the body. Conversely, adult stem cells are found in various tissues and organs throughout the body, where they contribute to tissue repair and regeneration. While adult stem cells have a more limited differentiation potential compared to ESCs, they remain a valuable resource for therapeutic applications.

Citations:

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.
Trounson, A., & McDonald, C. (2015). Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell, 17(1), 11-22.
Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-1147.
Trounson, A., & DeWitt, N. D. (2016). Pluripotent stem cells progressing to the clinic. Nature Reviews Molecular Cell Biology, 17(3), 194-200.
Daley, G. Q., et al. (2019). Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines. Stem Cell Reports, 12(6), 1216-1221.

MITAKY™ High-Tech Corporation Japan｜株式会社 ミタキ ハイテク日本

MITAKY Collaborates with Vietnam’s Ministry of Science and Technology on Agricultural Digitalisation in Thua Thien Hue

MITAKY Collaborates with Vietnam's Ministry of Science and Technology on Agricultural Digitalisation in Thua Thien Hue

About MITAKY

About Thua Thien Hue's Department of Science and Technology (MOST)

Further Reads

OUR Related Products & Services

MITAKY High-Tech Corporation｜Recruitment｜Regenerative Medical Liaison (Associate)

Regenerative Medical Liaison (Associates)

Starting Date:

Company Overview:

Position Summary:

Working Location (1):

Working Location (2):

Working Location (3):

Working Location (4):

Key Responsibilities:

Qualifications:

Our offers:

How to Apply:

Application Deadline:

Additional Information:

MITAKY High-Tech Corporation｜Recruitment｜Senior Medical Advisor

Senior Medical Adviser in MITAKY (Abu Dhabi)

Starting Date:

Company Overview:

Position Summary:

Working Location:

Key Responsibilities:

Qualifications:

Our offers:

How to Apply:

Application Deadline:

Additional Information:

MITAKY Technology Review｜Regenerative Medicine in Japan

Regenerative Medicine in Japan

Regenerative Medicine Products Market Size in Japan and Worldwide until 2050

Regenerative Medicine: A Paradigm Shift

Japan's Commitment to Regenerative Medicine

Breakthrough Products and Innovations in Japan

Regulatory Framework

Challenges

Future and Opportunities

References

Read more

Related reviews

MITAKY Technology Review｜Regenerative Medicine｜iPS Cells

iPS Cells (Induced Pluripotent Stem Cells)​

Summary

Understanding iPS Cells

Five Key Characteristics of iPS Cells

Applications of iPS Cells in Regenerative Medicine:

Challenges

A journey to stem cell research of Prof. Yamanaka

References

Read more

Related reviews

MITAKY Technology Review｜Regenerative Medicine｜Adipose-Derived Stem Cells

Adipose-Derived Stem Cells (ADSCs)

Summary

Understanding Adipose-Derived Stem Cells (ADSCs)

Characteristics and Properties of ADSCs

Four Applications of ADSCs in Regenerative Medicine

Challenges and Future Directions

Citations:

Related reviews

MITAKY Technology Review｜Regenerative Medicine｜Stem Cells

Stem Cells

Summary

Three key characteristics of stem cells

Types of Stem Cell Therapy

Applications in Regenerative Medicine

Recent Advances and Future Directions

Challenges and Ethical Considerations

Understanding Stem Cells

Citations:

Related reviews

MITAKY™ High-Tech Corporation Japan｜株式会社ミタキハイテク日本

iPS Cells (Induced Pluripotent Stem Cells)